Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
Public ClinicalTrials.gov record NCT01126970. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Multi-Center, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of 400 mg of Velneperit (S-2367) and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day With a Reduced Calorie Diet (RCD) in Obese Subjects
Study identification
- NCT ID
- NCT01126970
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Shionogi
- Industry
- Enrollment
- 486 participants
Conditions and interventions
Conditions
Interventions
- Velneperit 400 mg Drug
- Orlistat 120 mg Drug
- Orlistat Placebo Drug
- Velneperit Placebo Drug
- Reduced Calorie Diet Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2010
- Primary completion
- Dec 31, 2010
- Completion
- Jan 31, 2011
- Last update posted
- May 8, 2018
2010 – 2011
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Santa Rosa | California | — | — |
| Not listed | Waterbury | Connecticut | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Ponte Vedra | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Milford | Massachusetts | — | — |
| Not listed | North Dartmouth | Massachusetts | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Manlius | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Cary | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | New Braunfels | Texas | — | — |
| Not listed | Renton | Washington | — | — |
| Not listed | Wauwatosa | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01126970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01126970 live on ClinicalTrials.gov.